更昔洛韦治疗对巨细胞病毒诱导听力损失小鼠模型的影响
本研究在出生后第3天接种鼠巨细胞病毒的BALB/c小鼠中,评估更昔洛韦(GCV)对感音神经性听力损失的作用。GCV治疗组接受腹腔注射每日两次共14天,4周后ABR和DPOAE阈值均低于未治疗感染组(P<0.0001),病毒载量显著降低(P=0.03),外毛细胞总丢失约7% vs 14%(P<0.05)。结论认为GCV可改善听力并部分保护外毛细胞,似乎通过降低病毒载量实现。
要点
- GCV治疗组ABR和DPOAE阈值均低于未治疗感染组(P<0.0001)。
- GCV组病毒载量较未治疗感染组显著降低(P=0.03)。
- GCV组外毛细胞总丢失约7%,未治疗组约14%(P<0.05)。
核心结论
- 更昔洛韦在先天性巨细胞病毒感染的临床前模型中有效改善感音神经性听力损失,并部分保护外毛细胞,似乎通过降低病毒载量实现。
研究设计与样本
- 感染BALB/c小鼠于出生后第3天接种鼠巨细胞病毒,GCV治疗组接受腹腔注射每日两次共14天。
- 接种后4周采用畸变产物耳声发射(DPOAE)和听性脑干反应(ABR)评估听阈。
- 颞骨用于定量聚合酶链反应测定病毒载量及扫描电镜外毛细胞定量,自动血液分析仪完成中性粒细胞绝对计数(ANC)并人工复核确认。
主要发现
- GCV治疗组CMV感染小鼠ABR阈值低于未治疗感染组(P<0.0001,Kruskal-Wallis检验)。
- GCV治疗组DPOAE阈值低于未治疗感染组(P<0.0001)。
- GCV治疗组病毒载量较未治疗感染组显著降低(P=0.03)。
- GCV治疗组外毛细胞总丢失约7%,未治疗组约14%(P<0.05)。
- GCV单独治疗与未治疗未感染对照相比,ABR和DPOAE无显著差异(P=0.1,P=0.24)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether ganciclovir (GCV) treatment reduces sensorineural hearing loss in cytomegalovirus (CMV)-infected mice. The effects of GCV on viral load, absolute neutrophil count (ANC), and outer hair cell (OHC) integrity were also investigated. METHODS: Infected BALB/c mice were inoculated with murine CMV on postnatal day 3. Those treated with GCV received an intraperitoneal injection twice a day for 14 days. Auditory thresholds were assessed using distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) testing 4 weeks after inoculation. Temporal bones were used for determination of viral load by quantitative polymerase chain reaction and hair cell quantification by scanning electron microscopy. ANCs were completed by an automated hematology analyzer, with manual review for confirmation. RESULTS: GCV-treated CMV-infected mice had lower ABR (P < 0.0001, Kruskal-Wallis test) and DPOAE (P < 0.0001) thresholds compared to CMV-infected untreated mice, indicating that GCV protected mice from CMV-induced hearing loss. Viral load in infected populations undergoing GCV treatment was significantly decreased (P = 0.03) relative to untreated mice. GCV treatment alone had no effect on ABR and DPOAE compared to untreated, uninfected controls (P = 0.1, P = 0.24, respectively). GCV-treated mice received increased protection from OHC loss when compared to untreated groups, with total OHC losses of approximately 7% and 14%, respectively (P < 0.05). Neutropenia was absent after 7 days of GCV treatment. CONCLUSION: Ganciclovir effectively ameliorated SNHL and partially protected from OHC loss in a preclinical model of congenital CMV infection, seemingly by reducing viral load. LEVEL OF EVIDENCE: NA Laryngoscope, 130:1064-1069, 2020.
引用
- Haller TJ, Price MS, Lindsay SR, et al. Effects of ganciclovir treatment in a murine model of cytomegalovirus-induced hearing loss. Laryngoscope. 2019. PMID: 31184781. doi:10.1002/lary.28134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。